BloodPressureHeartMeds.Net

Indian wild plants offer hope against resistant infections

March 23, 2017

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib-(Nexavar?) treatment is planned for initiation in the second half of this year; this trial (TRAVERSE), conducted globally with Jennerex's partners, will evaluate survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"We are extremely encouraged by the promising overall survival results presented today. These results are consistent with a clinically meaningful survival benefit in patients with advanced liver cancer.  Given the large global unmet need in this patient population, we are confident to proceed into larger late-stage trials in advanced HCC patients with JX-594," stated Dr. Kirn.  "If a statistically-significant survival benefit with JX-594 is confirmed in larger randomized trials in HCC patients, JX-594 could represent a major new treatment option for these patients."

SOURCE Jennerex, Inc.